IGHE and allergic rhinitis: This paper tentatively proposes a multidimensional strategy for selecting biologic agents in allergic rhinitis (AR) based on key clinical trials, integrating serum IgE levels, disease phenotypes (seasonal/persistent), and comorbid conditions: omalizumab, which requires IgE-level individualized dosing, is suitable for patients with elevated IgE, while CM310 and dupilumab target type 2 inflammatory biomarkers (such as blood eosinophils and FeNO) with less dependence on IgE levels.